AstraZeneca Plc’s (NASDAQ:AZN) Chief Executive Pascal Soriot has called on the U.K. government to reconsider its approach to funding new medicines. The update comes after the National Institute for Care and Excellence (NICE) deemed the company’s new cancer drug, Enhertu, too expensive. Enhertu may not be available for treating a form of advanced breast cancer in England due to NICE’s decision. Related: AstraZeneca’s Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study. Soriot, while not committing to lower prices, emphasized the need for the new government to review how medicines are assessed. A course of Enhertu treatment costs £117,857 (roughly $151,695) at the list price, though the ...